CRIS Current Research Information System

CURTI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.687
AS - Asia 7.646
EU - Europa 5.178
AF - Africa 489
SA - Sud America 401
Continente sconosciuto - Info sul continente non disponibili 384
OC - Oceania 9
Totale 21.794
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.544
VN - Vietnam 2.067
CN - Cina 1.942
SG - Singapore 1.888
GB - Regno Unito 1.095
IT - Italia 1.040
SE - Svezia 821
DE - Germania 576
HK - Hong Kong 476
IN - India 341
FR - Francia 288
BR - Brasile 282
KR - Corea 262
NL - Olanda 234
RU - Federazione Russa 214
IE - Irlanda 175
UA - Ucraina 146
BD - Bangladesh 124
CI - Costa d'Avorio 110
ZA - Sudafrica 109
FI - Finlandia 104
JP - Giappone 103
TG - Togo 103
CA - Canada 85
GR - Grecia 73
JO - Giordania 71
BG - Bulgaria 70
CH - Svizzera 64
EE - Estonia 64
SC - Seychelles 63
AR - Argentina 56
PH - Filippine 48
NG - Nigeria 47
TR - Turchia 45
ID - Indonesia 42
TH - Thailandia 42
BE - Belgio 40
PL - Polonia 36
AT - Austria 33
ES - Italia 33
IR - Iran 29
MX - Messico 29
IQ - Iraq 27
TW - Taiwan 26
EU - Europa 18
EC - Ecuador 17
SA - Arabia Saudita 17
EG - Egitto 14
MY - Malesia 14
PK - Pakistan 14
UZ - Uzbekistan 13
LT - Lituania 12
PT - Portogallo 12
MA - Marocco 11
CL - Cile 9
CO - Colombia 9
HR - Croazia 9
VE - Venezuela 9
LB - Libano 8
MU - Mauritius 7
RO - Romania 7
TM - Turkmenistan 7
AU - Australia 6
CZ - Repubblica Ceca 6
OM - Oman 6
PE - Perù 6
QA - Qatar 5
UY - Uruguay 5
BB - Barbados 4
CR - Costa Rica 4
ET - Etiopia 4
IL - Israele 4
JM - Giamaica 4
KE - Kenya 4
KG - Kirghizistan 4
KZ - Kazakistan 4
PY - Paraguay 4
RS - Serbia 4
SN - Senegal 4
SV - El Salvador 4
AL - Albania 3
AZ - Azerbaigian 3
DZ - Algeria 3
GY - Guiana 3
HU - Ungheria 3
NO - Norvegia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
GD - Grenada 2
GT - Guatemala 2
HN - Honduras 2
KH - Cambogia 2
LI - Liechtenstein 2
MM - Myanmar 2
SI - Slovenia 2
Totale 21.406
Salva come PNG Salva come JPEG
Città #
Singapore 1.324
Southend 951
Ashburn 879
Chandler 642
Fairfield 599
Hefei 523
San Jose 521
Ho Chi Minh City 504
Hanoi 444
Hong Kong 443
Woodbridge 302
Wilmington 273
Ann Arbor 270
Santa Clara 266
Houston 253
Seattle 252
Beijing 229
Seoul 225
Cambridge 204
Princeton 203
Dong Ket 202
Bologna 195
Dublin 173
Dallas 171
Boardman 163
New York 137
Abidjan 110
Los Angeles 110
Lauterbourg 109
Lomé 103
Tokyo 92
Westminster 86
Milan 83
Nanjing 83
Helsinki 74
Padova 72
Amman 71
Haiphong 70
Sofia 68
Da Nang 65
Buffalo 64
Council Bluffs 63
Jacksonville 62
Frankfurt am Main 60
Bern 52
São Paulo 51
Berlin 48
Rome 48
Bremen 47
Redondo Beach 46
Bengaluru 45
Jinan 45
Munich 44
Hyderabad 43
San Diego 43
Turin 42
Shenyang 41
Brussels 40
Tianjin 39
Medford 33
Guangzhou 32
Saint Petersburg 32
Zhengzhou 32
Shanghai 31
Florence 30
Johannesburg 30
Abeokuta 29
Jakarta 27
Nanchang 27
Orem 25
Toronto 25
Atlanta 24
Biên Hòa 24
Hebei 24
London 24
Chicago 23
Quận Bình Thạnh 23
Redmond 23
Istanbul 22
Phoenix 21
Athens 20
Changsha 20
Hải Dương 20
Bangkok 19
Falkenstein 19
Hangzhou 19
Nuremberg 19
Redwood City 19
San Francisco 19
Warsaw 19
Can Tho 18
Jiaxing 18
Lappeenranta 18
Tongling 18
Ninh Bình 17
Amsterdam 16
Vienna 16
Des Moines 15
Mülheim 15
Norwalk 15
Totale 13.387
Salva come PNG Salva come JPEG
Nome #
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia 387
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 356
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 341
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 311
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 288
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 276
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 272
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 269
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 269
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 259
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 255
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 240
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 239
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 239
Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients 236
ATP release from chemotherapy-treated dying leukemia cells Elicits an immune suppressive effect by increasing regulatory T cells and Tolerogenic dendritic cells 234
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 232
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 232
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 231
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 229
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 228
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 227
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 224
A case report of acute myeloid leukemia and neurofibromatosis 1 223
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML 222
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 220
Immunosenescence and immunotherapy in elderly acute myeloid leukemia patients: Time for a biology-driven approach 219
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 218
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 213
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 212
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. 212
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 210
Flow cytometry analysis of T-cell subsets in cerebrospinal fluid of narcolepsy type 1 patients with long-lasting disease 210
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 210
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 207
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 206
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms 203
Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. 202
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 200
The more, the better: "Do the right thing" for natural killer immunotherapy in acute myeloid leukemia 199
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 198
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 197
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 196
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 191
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 190
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia 190
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 190
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 189
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 188
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy 187
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response 186
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 186
Corrigendum: Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells (Front. Oncol, (2020), 10, (1225), 10.3389/fonc.2020.01225) 185
Extracellular ATP exerts opposite effects on activated and regulatory CD4 + T cells via purinergic P2 receptor activation 184
Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells 184
Dendritic cell differentiation. 183
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 182
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 181
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 181
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 180
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 180
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 180
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 177
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 174
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 174
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 174
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. 172
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 172
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 171
Immune characterization in Narcolepsy Type 1. 171
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 166
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. 166
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 165
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 164
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 157
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 157
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 157
Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells 155
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 155
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 154
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 153
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 150
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 150
Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade 150
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 144
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 144
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 144
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 141
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study 140
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 139
The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia 138
Emerging bone marrow microenvironment‐driven mechanisms of drug resistance in acute myeloid leukemia: Tangle or chance? 138
More ADO about IDO: GVHD. 136
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 134
FLUDARABINE, CYTARABINE, IDARUBICIN AND ETOPOSIDE (FLAIE) SCHEDULE IS SAFE AND ACTIVE FOR YOUNG PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF A MULTICENTRIC PHASE III ITALIAN STUDY 131
A phase I study of Tipifarnib and Bortezomib in the treatment of poor risk adult acute myeloid leukemia (AML) 130
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 129
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 129
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 129
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 128
Totale 19.526
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.743
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.233 153 67 131 226 193 128 45 168 127 191 415 389
2022/20232.587 331 401 124 321 188 201 81 149 421 50 170 150
2023/2024756 49 110 41 99 57 170 39 35 27 38 66 25
2024/20253.023 151 372 225 206 407 150 196 95 74 300 217 630
2025/20268.368 1.022 1.103 680 673 706 329 689 349 1.606 617 303 291
2026/2027186 186 0 0 0 0 0 0 0 0 0 0 0
Totale 21.794